PODD
Insulet Corporation NASDAQ Listed May 15, 2007$160.39
Mkt Cap $11.1B
52w Low $148.31
5.8% of range
52w High $354.88
50d MA $210.86
200d MA $280.25
P/E (TTM)
49.9x
EV/EBITDA
34.6x
P/B
8.1x
Debt/Equity
0.7x
ROE
16.3%
P/FCF
52.9x
RSI (14)
—
ATR (14)
—
Beta
1.47
50d MA
$210.86
200d MA
$280.25
Avg Volume
997.4K
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
100 Nagog Park · Acton, MA 01720 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | TNS | 1.19 | 1.42 | +19.3% | 151.28 | +1.2% | +6.0% | — | — | — | — | — |
| Feb 18, 2026 | TNS | 1.47 | 1.55 | +5.4% | 258.07 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% | — |
| Nov 6, 2025 | TNS | 1.14 | 1.24 | +8.8% | 323.40 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% | — |
| Aug 7, 2025 | TNS | 0.92 | 1.17 | +27.2% | 303.55 | +0.0% | +1.2% | -0.7% | +1.6% | -0.3% | +2.3% | — |
| May 8, 2025 | TNS | 0.79 | 1.02 | +29.1% | 257.00 | +14.0% | +20.9% | +1.9% | -0.7% | +2.2% | +0.2% | — |
| Feb 20, 2025 | TNS | 1.00 | 1.15 | +15.0% | 288.29 | -4.1% | -1.9% | +0.2% | -5.9% | +1.5% | -1.3% | — |
| Nov 7, 2024 | TNS | 0.76 | 0.90 | +18.4% | 244.98 | +4.9% | +9.4% | +2.9% | -0.2% | -2.2% | -2.9% | — |
| Aug 8, 2024 | TNS | 0.56 | 0.55 | -2.5% | 199.79 | -12.8% | -8.8% | +3.2% | +3.5% | -1.6% | +1.8% | — |
| May 9, 2024 | TNS | 0.39 | 0.73 | +87.2% | 177.53 | +2.4% | -6.6% | -2.9% | +7.0% | +4.8% | +2.7% | — |
| Feb 22, 2024 | TNS | 0.66 | 1.40 | +112.1% | 197.14 | -6.2% | -6.6% | -8.3% | -1.3% | -1.8% | +0.2% | — |
| Nov 2, 2023 | TNS | 0.40 | 0.71 | +77.5% | 140.44 | +11.1% | +15.8% | -2.3% | +1.9% | -4.3% | -1.3% | — |
| Aug 8, 2023 | TNS | 0.26 | 0.38 | +46.2% | 238.34 | -1.4% | -3.6% | +1.7% | -3.6% | -0.6% | -2.1% | — |
| May 4, 2023 | BMO | 0.09 | 0.23 | +155.6% | 322.23 | +1.2% | +2.0% | -3.0% | +0.2% | +1.0% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Rothschild & Co Redburn | Downgrade | Buy → Neutral | $220 | $192.21 | $188.85 | -1.7% | -1.4% | -0.7% | -2.9% | -12.5% | +7.6% |
| Apr 24 | Rothschild & Co | Downgrade | Buy → Neutral | — | $192.21 | $188.85 | -1.7% | -1.4% | -0.7% | -2.9% | -12.5% | +7.6% |
| Apr 15 | Truist | Maintains | Buy → Buy | — | $201.49 | $202.82 | +0.7% | +0.5% | -0.5% | +1.1% | -1.4% | -4.3% |
| Apr 9 | Goldman Sachs | Maintains | Buy → Buy | — | $203.51 | $201.67 | -0.9% | -2.0% | -1.2% | +0.4% | +1.9% | +0.5% |
| Apr 7 | Citigroup | Downgrade | Buy → Neutral | — | $203.50 | $200.55 | -1.4% | -0.5% | +0.5% | -2.0% | -1.2% | +0.4% |
| Mar 11 | Citigroup | Maintains | Buy → Buy | — | $238.24 | $236.85 | -0.6% | +0.2% | -1.2% | -6.9% | +2.2% | +2.6% |
| Feb 19 | Canaccord Genuity | Maintains | Buy → Buy | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Truist | Maintains | Buy → Buy | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Bernstein | Maintains | Outperform → Outperform | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Evercore ISI | Maintains | Outperform → Outperform | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Citigroup | Maintains | Buy → Buy | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Goldman Sachs | Maintains | Buy → Buy | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | JP Morgan | Maintains | Overweight → Overweight | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Leerink Partners | Maintains | Outperform → Outperform | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 18 | BTIG | Maintains | Buy → Buy | — | $246.34 | $266.00 | +8.0% | +4.8% | -3.5% | -2.9% | +3.1% | -1.7% |
| Feb 4 | Stifel | Maintains | Buy → Buy | — | $251.22 | $253.19 | +0.8% | +0.0% | -3.2% | -0.5% | +1.5% | +2.8% |
| Jan 12 | Barclays | Downgrade | Equal Weight → Underweight | — | $289.04 | $286.71 | -0.8% | -3.6% | -0.1% | +1.7% | +1.3% | +0.4% |
| Jan 9 | Bernstein | Maintains | Outperform → Outperform | — | $292.89 | $293.08 | +0.1% | -1.3% | -3.6% | -0.1% | +1.7% | +1.3% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $289.57 | $292.19 | +0.9% | +1.1% | -1.1% | +0.7% | -2.1% | +1.2% |
| Dec 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $288.73 | $288.81 | +0.0% | +0.3% | +1.1% | -1.1% | +0.7% | -2.1% |
| Nov 24 | Canaccord Genuity | Maintains | Buy → Buy | — | $331.17 | $330.03 | -0.3% | +1.9% | -2.6% | -0.6% | +0.1% | -5.0% |
| Nov 21 | Truist | Maintains | Buy → Buy | — | $312.89 | $321.96 | +2.9% | +5.8% | +1.9% | -2.6% | -0.6% | +0.1% |
| Nov 21 | BTIG | Maintains | Buy → Buy | — | $312.89 | $321.96 | +2.9% | +5.8% | +1.9% | -2.6% | -0.6% | +0.1% |
| Nov 21 | RBC Capital | Maintains | Outperform → Outperform | — | $312.89 | $321.96 | +2.9% | +5.8% | +1.9% | -2.6% | -0.6% | +0.1% |
| Nov 19 | UBS | Upgrade | Neutral → Buy | — | $333.47 | $340.24 | +2.0% | +3.9% | -9.7% | +5.8% | +1.9% | -2.6% |
| Nov 13 | BTIG | Maintains | Buy → Buy | — | $336.84 | $334.87 | -0.6% | -1.2% | +0.0% | -1.4% | +1.7% | +3.9% |
| Nov 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 7 | UBS | Maintains | Neutral → Neutral | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 7 | Truist | Maintains | Buy → Buy | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 7 | RBC Capital | Maintains | Outperform → Outperform | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 6 | Jefferies | Maintains | Buy → Buy | — | $314.44 | $323.49 | +2.9% | +2.8% | -1.1% | +0.2% | +1.9% | +3.2% |
| Nov 5 | Barclays | Maintains | Equal Weight → Equal Weight | — | $320.27 | $315.23 | -1.6% | -1.8% | +2.8% | -1.1% | +0.2% | +1.9% |
| Sep 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $318.00 | $319.60 | +0.5% | -2.3% | -0.6% | -0.9% | +2.0% | -1.0% |
| Sep 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $348.43 | $349.56 | +0.3% | +0.3% | +0.9% | -4.3% | +0.1% | +1.1% |
| Aug 21 | Barclays | Maintains | Equal Weight → Equal Weight | — | $333.00 | $332.23 | -0.2% | -1.5% | +0.9% | -0.5% | +0.9% | +0.8% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $303.55 | $303.55 | +0.0% | +1.2% | -0.7% | +1.6% | -0.3% | +2.3% |
| Aug 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $303.55 | $303.55 | +0.0% | +1.2% | -0.7% | +1.6% | -0.3% | +2.3% |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $303.55 | $303.55 | +0.0% | +1.2% | -0.7% | +1.6% | -0.3% | +2.3% |
| May 27 | Raymond James | Maintains | Outperform → Outperform | — | $321.36 | $325.00 | +1.1% | +1.6% | -0.9% | +0.1% | +0.4% | -0.0% |
| May 22 | Citigroup | Maintains | Buy → Buy | — | $324.50 | $324.00 | -0.2% | -1.1% | +0.1% | +1.6% | -0.9% | +0.1% |
| May 13 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $316.67 | $316.67 | +0.0% | -0.7% | +2.2% | +0.2% | +0.8% | +0.3% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $257.00 | $293.03 | +14.0% | +20.9% | +1.9% | -0.7% | +2.2% | +0.2% |
| Apr 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $251.27 | $249.55 | -0.7% | +0.4% | -0.8% | +2.7% | +0.7% | +0.0% |
| Apr 29 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $259.52 | $255.65 | -1.5% | -3.2% | +0.4% | -0.8% | +2.7% | +0.7% |
| Feb 21 | Citigroup | Maintains | Buy → Buy | — | $288.29 | $276.35 | -4.1% | -1.9% | +0.2% | -5.9% | +1.5% | -1.3% |
| Feb 21 | Raymond James | Maintains | Outperform → Outperform | — | $288.29 | $276.35 | -4.1% | -1.9% | +0.2% | -5.9% | +1.5% | -1.3% |
| Feb 21 | Piper Sandler | Maintains | Overweight → Overweight | — | $288.29 | $276.35 | -4.1% | -1.9% | +0.2% | -5.9% | +1.5% | -1.3% |
No insider trades available.
8-K · 7.01
! Medium
Insulet Corporation -- 8-K 7.01: Regulation FD Disclosure
Insulet Corporation disclosed 18 serious adverse event reports related to its insulin pump devices, prompting a customer communication update on April 10, 2026, which may impact investor confidence and regulatory standing.
Apr 29
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Insulet Corporation disclosed forward-looking statements with standard cautionary language, indicating management won't proactively update projections unless legally required, so investors should independently reassess PODD's outlook regularly.
Mar 12
8-K · 5.02
!!! Very High
Insulet Corporation -- 8-K 5.02: Executive Change
Insulet Corporation's former CFO Chadwick departed under standard severance terms previously disclosed, with no additional material compensation beyond existing plan provisions.
Mar 4
8-K · 4.01
!!! Very High
Insulet Corporation -- 8-K 4.01: Auditor Change / Resignation
Insulet Corporation (PODD) replaced auditor GT with PwC for fiscal 2026, a routine transition that suggests no material accounting disputes and maintains audit oversight continuity.
Feb 24
8-K
Insulet Corporation -- 8-K Filing
Insulet completed a $60 million share repurchase and plans approximately $300 million in repurchases during Q1 2026, signaling management confidence and commitment to returning capital to shareholders.
Feb 18
8-K · 1.01
!! High
Insulet Corporation -- 8-K 1.01: Material Agreement
Insulet Corporation extended its existing supply agreement with NXP USA through a 2026 addendum, securing continued semiconductor components for its insulin pump devices.
Feb 3
Data updated apr 26, 2026 8:20pm
· Source: massive.com